REFERENCES
- Takahashi Y., Bucana C. D., Liu W, et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146–1151
- Takahashi Y., Ellis L. M., Mai M. The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep 2003; 10: 9–13
- Takebayashi Y., Akiyama S., Akiba S., et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88: 1110–1117
- De Bruin M., Van Capel T., Smid K., et al. The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase. Eur J Pharmacol 2004; 491: 93–99
- Emura T., Suzuki N., Yamaguchi M., Ohshimo H., Fukushima M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 2004; 25: 571–578
- Temmink O. H., Emura T., de Bruin M., Fukushima M., Peters G. J. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007; 98(6)779–789
- Ansfield F. J., Ramirez G. Phase I and II studies of 2′-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 1971; 55: 205–208
- Heidelberger C., Dexter D. L., Wolberg W. H. Clinical pharmacology of 5-trifluoromethyl-2-deoxyuridine (F3 TDR). Proc Am Assoc Cancer Res 1970; 35
- Emura T., Nakagawa F., Fujioka A., et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004; 13: 249–255
- Hong D. S., Abbruzzese J. L., Bogaard K., , Phase I, et al. study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 2006; 107: 1383–1390
- Dwivedy S., Hoff P. M., Dumas P., et al. Safety and Pharmacokinetics (PK) of an Antitumor/Antiangiogenic Agent, TAS-102: a Phase I Study for Patients (PTS) with Solid Tumors. J Clin Oncol 2001; 20, Abstract 386.
- Thomas M. B., Hoff P. M., Carter S., et al. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five days every three weeks in patients with solid tumors. Paper presented at: Proc Am Assoc Cancer Res 2002; 43, Abstract 2754.
- Therasse P., Arbuck S. G., Eisenhauer E. A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216
- Green M. C., Pusztai L., Theriault R. L., , Phase I, et al. study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology 2006; 24, Abstract 10576.